Is Ozempic maker stock a buy after OpenAI partnership?

Novo Nordisk (NYSE: NVO), the company behind the blockbuster diabetes and weight-loss drug Ozempic, has announced a strategic partnership with OpenAI.

The collaboration will integrate advanced artificial intelligence across its operations, from drug discovery and development to manufacturing, supply chains, distribution, and commercial functions, to accelerate the delivery of improved treatments.

Pilot programs are already underway in research, manufacturing, and commercial teams, with full global integration targeted by the end of 2026.

OpenAI will also support workforce upskilling to enhance AI literacy, positioning Novo Nordisk at the forefront of healthcare AI transformation.

The announcement comes amid a challenging NVO stock environment. Shares closed at $37.98 on Monday, up 1.23%, before rising to $38.97 in pre-market trading on April 14, a 2.61% gain as investors reacted to the news.

Over the past year, the stock has declined 42%, trading well below its 2025 highs within a volatile 52-week range, pressured by competition from Eli Lilly in the GLP-1 market.

What’s next for NVO stock price 

Notably, analyst sentiment, based on eight Wall Street firms tracked by TipRanks, remains cautious, with a consensus ‘Hold’ rating that includes one ‘Buy’ and seven ‘Hold’ recommendations.

The average 12-month price target is $43, implying about 13.22% upside from the April 13 close, with estimates ranging from $40 to $47.

Fundamentally, Novo Nordisk ended 2025 on a strong note, posting fourth-quarter earnings per share of $1.01, above the $0.90 estimate, and revenue of $12.43 billion, beating forecasts of $11.97 billion. Full-year results also showed solid growth in sales and operating profit at constant exchange rates.

However, the 2026 outlook is more subdued, with adjusted sales and operating profit expected to decline between 5% and 13% due to U.S. pricing pressures and one-off factors. The company’s next earnings report, due May 6, is expected to show EPS of $0.87 to $0.89 and revenue of about $11.22 billion.

Despite near-term pressure, strong demand for Ozempic, Wegovy, and the broader GLP-1 portfolio continues to support long-term growth, aided by pipeline progress and share buybacks.

OpenAI halo effect

At the same time, history shows that OpenAI partnerships can trigger sharp stock rallies, especially for direct infrastructure or revenue beneficiaries. 

For instance, Advanced Micro Devices (NASDAQ: AMD) surged over 30% in a single session and as much as 43% in a week after announcing an AI chip deal with OpenAI. 

Broadcom (NASDAQ: AVGO) gained nearly 10% on news of a custom chip agreement, while Oracle jumped 36% in one day, its biggest rise since 1992, tied to a large computing backlog involving OpenAI. 

These moves highlight the so-called OpenAI halo effect, where association with the AI leader drives investor enthusiasm and market-cap gains.

For Novo Nordisk, the partnership adds a forward-looking catalyst that could enhance drug discovery, efficiency, and long-term earnings.

In a competitive obesity and diabetes market, it may serve as a key differentiator, though cautious analyst sentiment and recent stock weakness suggest the benefits may take time to materialize.

The stock’s appeal depends on an investor’s time horizon and confidence in AI-driven innovation. 

Unlike the sharp rallies seen in tech firms tied directly to OpenAI infrastructure, Novo’s deal centers on internal transformation, pointing to more gradual upside.